FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

PD/4-32749A APPLICATION NO. 10/534,790 APPLICANT Margaret Forney Prescott FILING DATE JULY 20, 2005

Group

Sheet 1 of 3

T (#Use several sheets If necessary) APR 1 1 2006

EXAMINER

/Nissa Westerberg/

U.S. PATENT DOCUMENTS

PADEMAN			0.0.				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,471,980	10/29/02	Sirhan et al.			
	AB	2002/0035395	3/21/02	Sugimoto			
	AC	2002/0082677	6/27/02	Sirhan et al.			
	AD	2002/0082678	6/27/02	Sirhan et al.			
	AE	2002/0082679	6/27/02	Sirhan et al.			
	AF	2002/0082685	6/27/02	Sirhan et al.			
	AG	2002/0114823	8/22/02	Sirhan et al.			
	АН	2003/0033004	2/13/03	Ishii et al.			
	Al	2003/0033007	2/13/03	Sirhan et al.			
	AJ	2004/0117008	6/17/04	Wnendt et al.			
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
A	М	20 202 150	7/31/03	DE (abstract)				
A	N	0 970 711	10/13/04	EP				
A	0	1 159 934	12/5/01	EP				
A	Р	1 254 674	9/15/04	EP				
A	Q	1 273 314	1/8/03	EP				

OTHER DOCUMENTS (Including Author Title Date Pertinent pages Etc.)

	OTTER DOCUMENTO (medianing Addition, Title, Date, Fertilinent pages, Etc.)
AR	Alt et al., "Implantation of Tacrolimus Coated Stents in the Pig", Circulation, Vol. 106, No. 19, Suppl., pp. II.448 (2002) Abstract No. 2003:77419.
 AS	Avery, "Cardiac-Allograft Vasculopathy", N. Engl. J. Med., Vol. 349, No. 9, pp. 829-830 (2003).
АТ	Babapulle et al., "Coated Stents for the Prevention of Restenosis: Part II", Circulation, Vol. 106, pp. 2859-2866 (2002).

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

DATE CONSIDERED

06/01/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M.W./

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(Use several sheets if necessary)

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

PDI/4-32749A APPLICATION NO. 10/534,790 APPLICANT Margaret Forney Prescott FILING DATE JULY 20, 2005

Sheet 2 of 3

Group

FOREIGN PATENT DOCUMENTS

XAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATIC
	ВА	02/056790	7/25/02	wo				
	вв	02/065947	8/29/02	WO (English Equiv. is US 2004/0117008)				
	вс	02/087586	11/7/02	wo				
	BD	03/009777	2/6/03	wo				
	BE	03/009778	2/6/03	wo				
	BF	03/009779	2/6/03	wo				
	BG							
	вн							
	ВІ							
	BJ							
	BK							
	BL							
	вм							
	BN							
	во							
	BP							
	BQ							
	BR	-			,			
	BS							
	вт							
	BU							
	BV							
	BW							
	BX							
	BY							
	BZ							
XAMIN	ER	/Nissa Westerberg	V	DATE CONSIDERED	06/01/200	9		

conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

(REV. 7-85) INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. PD/4-32749A APPLICATION NO. 10/534,790 APPLICANT Margaret Forney Prescott FILING DATE JULY 20, 2005

Group

Sheet 3 of 3

	СА	Chieffo et al., "Drug-Eluting Stents", Minerva Cardioangiologica, Vol. 50, No. 5, pp. 419-429 (2002) - Abstract No. 2002417593.
	СВ	Eisen et al., "Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac- Transplant Recipients", N. Engl. J. Med., Vol. 349, No. 9, pp. 847-858 (2003).
	СС	Grube et al., "Initial Experience with Paclitaxel-Coated Stents", Journal of Interventional Cardiology, Vol. 15, No. 6, pp. 471-475 (2002) — Abstract No. 2002715160.
	CD	Grube et al., "Drug Eluting Stents: Intial Experiences", Zeitschrift fuer Kardiologie, Vol. 91, Suppl. 3 pp. 44-48 (2002).
	CE	Grube et al, "Drug-Eluting Stents: Clinical Experiences and Perspectives", Minerva Cardioangiologica, Vol. 50, No. 5, pp. 469-473 (2002) Abstract No. 2002626774.
	CF	Kandzari et al, "Coronary Artery Stents: Evaluating New Designs for Contemporary Percutaneous Intervention", Catheterization and Cardiovascular Interventions, Vol. 56, No. 4, pp. 562-576 (2002), MEDLINE Entry for this article.
	CG	Matter et al., "Tacrolimus (FK506), but no Sirolimus (Rapamycin) Targets Human Vascular Smooth Muscle Cells (VSMC), but Spares Endothelial Cells (EC): Implications for Drug-Eluting Stents", Circulation, Vol. 106, No. 19 Suppl., pp. II.356-II.357 (2002). BIOSIS ENTEY.
	СН	Meingassner et al., "A Novel Anti-Inflammatory Drug, SDZ ASM 981, for the Topical and Oral Treatment of Skin Diseases: in vivo Pharmacology", British Journal of Dermatology, Vol. 137, pp 568-576 (1997).
	СІ	Muller et al., "State of Treatment of Coronary Artery Disease by Drug Releasing Stents", Herz, Vol. 27, No. 6, pp. 508-513 (2002). MEDLINE entry
	Cl	Poerner et al., "Drug-Coated Stents", Minimally Invasive Therapy and Allied Technologies, Vol. 11, No. 4, pp. 185-192 (2002). EMBASE entry
	ск	Presbitero et al., "Drug-Eluting Stents Do They Make the Difference?", Minera Cardioangiologica, Vol. 50, No. 5, pp. 431-442 (2002). MEDLINE Entry
	CL	Stuetz et al., "Pimecrolimus (Elidel, SDZ ASM 981)Preclinical Pharmacologic Profile and Skin Selectivity", Seminars in Cutaneous Medicine and Surgery, Vol. 20, No. 4, pp. 233-241 (2001).
	СМ	Vetrovec, "Drug-Eluting Stents: Current Outcomes and Potential Impact on Coronary Disease Management", Journal of Invasive Cardiology, Vol. 14, No. 11, pp. 709-712 (2002).
	CN	Wieneke et al., "Stent Coating: A New Approach in Interventional Cardiology", Herz, Vol. 27, No. 6, pp. 518-526 (2002).
EXAMINE	L	DATE CONSIDERED 06/01/2009

/Nissa Westerberg/
*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.M.W./